Pharma procurement blindsided as supply shocks expose data gap

Pharmaceutical supply chains are under renewed strain as disruption in the Middle East forces widespread rerouting of air and sea freight, delaying shipments and tightening capacity across global trade routes.

For drugmakers, the impact is acute. Longer transit times increase the risk of temperature excursions for sensitive medicines, shorten shelf life and, in some cases, lead to total shipment losses. With up to 20 per cent of global pharmaceutical trade passing through the region, the disruption is feeding through into higher costs and reduced reliability worldwide.

The episode is exposing a deeper structural issue. Procurement teams remain heavily reliant on relationship-led models, which can lag behind fast-moving market conditions. While adoption of data-driven tools is increasing, many organisations still lack real-time visibility into pricing, capacity and disruption signals.

Industry data suggest the consequences are widespread. Companies report rising contingency costs, last-minute logistics changes and growing instances of delays and stockouts when disruption is identified too late.

The result is a widening gap between how procurement operates and how freight markets behave. As volatility becomes a constant feature rather than a periodic shock, companies with access to real-time market intelligence are better positioned to anticipate change, control costs and protect supply.